Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Triggiani

Showing results (81-90 of 146) with videos related to

Pageof 15
Sort By:
ERJ Open Research|November 1, 2023
Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitisAndrea Portacci, Raffaele Campisi, Enrico Buonamico, et al.
Frontiers in Immunology|July 17, 2023
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational studySanti Nolasco, Andrea Portacci, Raffaele Campisi, et al.
International Archives of Allergy and Immunology|November 2, 2011
Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposalPeter Valent, Cem Akin, Michel Arock, et al.
Journal of Clinical Medicine|September 13, 2025
The LUNET Project: Developing the Italian Systemic Erythematous Lupus NetworkIlaria Mormile, Luisa Brussino, Giorgio Walter Canonica, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|October 11, 2024
Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With MepolizumabDanilo Di Bona, Massimo Bilancia, Claudia Crimi, et al.
Vaccines|April 28, 2023
Multicentric Observational Study on Safety and Tolerability of COVID-19 Vaccines in Patients with Angioedema with C1 Inhibitor Deficiency: Data from Italian Network on Hereditary and Acquired Angioedema (ITACA)Roberta Parente, Silvio Sartorio, Luisa Brussino, et al.
Frontiers in Immunology|April 17, 2023
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polypsCorrado Pelaia, Alida Benfante, Maria Teresa Busceti, et al.
Rheumatology and Therapy|April 12, 2026
Achievement and Maintenance of Remission with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in Italy: 1-Year Data from UPHOLD, a Prospective Real-World Observational StudyCaterina Baldi, Eleonora Celletti, Serena Bugatti, et al.
The World Allergy Organization Journal|February 24, 2016
Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseasesDean D Metcalfe, Ruby Pawankar, Steven J Ackerman, et al.
Journal of Clinical Medicine|February 27, 2026
Effectiveness and Safety of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps and Associated T2 Comorbidities: One-Year Real Life RoundEustachio Nettis, Rossella Casella, Elisabetta Di Leo, et al.
Pageof 15

Showing results (81-90 of 146) with videos related to

Sort By:
Pageof 15
ERJ Open Research|November 1, 2023
Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitisAndrea Portacci, Raffaele Campisi, Enrico Buonamico, et al.
Frontiers in Immunology|July 17, 2023
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational studySanti Nolasco, Andrea Portacci, Raffaele Campisi, et al.
International Archives of Allergy and Immunology|November 2, 2011
Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposalPeter Valent, Cem Akin, Michel Arock, et al.
Journal of Clinical Medicine|September 13, 2025
The LUNET Project: Developing the Italian Systemic Erythematous Lupus NetworkIlaria Mormile, Luisa Brussino, Giorgio Walter Canonica, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|October 11, 2024
Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With MepolizumabDanilo Di Bona, Massimo Bilancia, Claudia Crimi, et al.
Vaccines|April 28, 2023
Multicentric Observational Study on Safety and Tolerability of COVID-19 Vaccines in Patients with Angioedema with C1 Inhibitor Deficiency: Data from Italian Network on Hereditary and Acquired Angioedema (ITACA)Roberta Parente, Silvio Sartorio, Luisa Brussino, et al.
Frontiers in Immunology|April 17, 2023
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polypsCorrado Pelaia, Alida Benfante, Maria Teresa Busceti, et al.
Rheumatology and Therapy|April 12, 2026
Achievement and Maintenance of Remission with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in Italy: 1-Year Data from UPHOLD, a Prospective Real-World Observational StudyCaterina Baldi, Eleonora Celletti, Serena Bugatti, et al.
The World Allergy Organization Journal|February 24, 2016
Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseasesDean D Metcalfe, Ruby Pawankar, Steven J Ackerman, et al.
Journal of Clinical Medicine|February 27, 2026
Effectiveness and Safety of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps and Associated T2 Comorbidities: One-Year Real Life RoundEustachio Nettis, Rossella Casella, Elisabetta Di Leo, et al.
Pageof 15